<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Moses McCarthy | Activity</title>
	<link>https://www.catswannabecats.com/members/tastesearch8/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/tastesearch8/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Moses McCarthy.</description>
	<lastBuildDate>Sat, 04 Jul 2026 08:03:39 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">e87d0d5fbeb5242ce98312dcc35253d9</guid>
				<title>Moses McCarthy posted an update: Furthermore, the reduced susceptibility to itraconazole and [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/17812/</link>
				<pubDate>Tue, 03 Jun 2025 09:14:59 -0400</pubDate>

									<content:encoded><![CDATA[<p>Furthermore, the reduced susceptibility to itraconazole and voriconazole was overcome by milbemycin oxime.</p>
<p> In conclusion, our study shed more light on the role of the ABC transporter family in T. mentagrophytes, which, if overexpressed, can confer resistance to single azole drugs and even cross-resistance. Finally, milbemycin oxime could&hellip;<span class="activity-read-more" id="activity-read-more-17812"><a href="https://www.catswannabecats.com/activity/p/17812/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">2d43512220034e38ec70240b02d73e6a</guid>
				<title>Moses McCarthy posted an update: Immunotherapy with anti-disialoganglioside dinutuximab has [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/7670/</link>
				<pubDate>Sat, 31 May 2025 19:45:30 -0400</pubDate>

									<content:encoded><![CDATA[<p>Immunotherapy with anti-disialoganglioside dinutuximab has improved survival for children with high-risk neuroblastoma (NB) when given after induction chemotherapy and surgery. However, disease recurrence and resistance persist. Dinutuximab efficacy has not been evaluated when initiated before primary tumor removal. Using a surgical mouse model of&hellip;<span class="activity-read-more" id="activity-read-more-7670"><a href="https://www.catswannabecats.com/activity/p/7670/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">212e93a44c6d015c16d2004b62dd0cde</guid>
				<title>Moses McCarthy became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/7542/</link>
				<pubDate>Sat, 31 May 2025 19:31:29 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>